Product news from the 10/31/06 News Brief

Share this article:
The FDA has approved Novartis’ Tyzeka (telbivudine) for patients with chronic hepatitis B. Alpharma won FDA approval for its 80 mg dosage strength of chronic pain treatment Kadian (morphine sulfate). The company expects to launch this new dosage strength during the fourth-quarter of 2006. Kadian is currently marketed in 20mg, 30mg, 50mg, 60mg and 100mg dosages.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Avastin pockets another Priority Review label

It's the second for this cancer drug in two weeks.

Court invalidates some healthcare subsidies

The lawsuit has been wending its way through the courts for a while, and, although it is being deliberated in several other venues, the decision is part of a legal dispute that puts patients in the 36 states offering federal exchanges in limbo.

FDA generic division overhaul kicks in

The Food and Drug Administration has been intent on elevating and reorganizing its office of Generic Drugs since 2012.